| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.095 | 0.01 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.095 | 0.02 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.086 | 0.02 |